High-concentration monoclonal antibody (mAb) formulations are progressively required for subcutaneous (SC) administration to support patient-centric dosing and decrease healthcare burden. However, achieving concentrations above 100–150 mg/mL presents substantial formulation challenges, including elevated viscosity, reversible self-association, opalescence, aggregation, and chemical degradation, which can compromise manufacturability, stability, and device compatibility. These behaviors arise from complex intermolecular interactions such as electrostatic forces, hydrophobic surface patches, aromatic and cation–p interactions, and glycosylation-dependent structural features. Recent advances in biophysical characterization techniques, including dynamic and static light scattering (DLS/SLS), sedimentation velocity analytical ultracentrifugation (SVAUC), and microrheology, together with computational modeling and machine learning (ML)-based developability tools, enable early identification of viscosity problems and aggregation risks. To address these challenges, several formulation strategies have been explored. Amino-acid additives such as arginine or histidine can reduce attractive protein–protein interactions and improve solution rheology, while emerging excipients including ionic liquids enhance protein solubility and structural stability. PEGylation and targeted protein engineering approaches further help minimize intermolecular association. In parallel, co-optimization of formulation rheology with device mechanics and the use of recombinant human hyaluronidase PH20 (rHuPH20) support efficient large-volume SC delivery. Embedding these approaches within a Quality by Design (QbD) framework supports robust development of high-concentration antibody therapeutics.